Quantcast

Latest Cancer treatments Stories

2014-10-16 23:03:38

Lawrence Livermore biomedical researcher Mike Malfatti is working with two researchers at the University of California, Davis, Comprehensive Cancer Center to leverage dramatic advances in biological accelerator mass spectrometry (AMS) to see how cancer patients respond to the chemotherapeutic drug carboplatin. Livermore, California (PRWEB) October 16, 2014 Buoyed by several dramatic advances, Lawrence Livermore National Laboratory scientists think they can tackle biological science in a...

2014-10-15 12:32:29

LONDON, Oct. 15. 30, 2014 /PRNewswire/ -- REPORT HIGHLIGHTS The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018. This report provides:An overview of the global market for cancer immunotherapiesAnalyses of global market trends, with data from 2012, estimates for 2013, and projections of...

2014-10-14 08:33:18

SAN RAFAEL, Calif., Oct. 14, 2014 /PRNewswire/ -- Sanovas Inc., a Life Science company accelerating the development and commercialization of next-generation microinvasive diagnostics, devices and drug delivery technologies, announced today that US Patent No. 8,834,544 has issued to the Company. Photo - http://photos.prnewswire.com/prnh/20141013/151744 Logo - http://photos.prnewswire.com/prnh/20141013/151743LOGO The patent, entitled "Photodynamic Therapy for Tumors...

2014-10-09 08:27:59

DelMar Pharmaceuticals Presents Data at AACR's New Horizons in Cancer Research Conference in Shanghai, China VANCOUVER, British Columbia, MENLO PARK, Calif. and SHANGHAI, Oct. 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research:...

2014-10-07 08:28:48

University of Mannheim Medical Center is first site opened TORONTO and CHICAGO, Oct. 7, 2014 /PRNewswire/ - Pinnacle Biologics, Inc. ("Pinnacle"), a subsidiary of Concordia Healthcare Corp., ("Concordia") (TSX: CXR) (OTCQX: CHEHF), announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy. OPUS is an Open-label, multicenter phase 3 on the efficacy and safety of Photodynamic...

2014-10-02 12:28:31

LONDON, Oct. 2, 2014 /PRNewswire/ -- This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the...

2014-10-02 08:24:49

LUGANO, Switzerland, October 2, 2014 /PRNewswire/ -- Rare cancer patients need access to innovative cancer drugs A consensus paper published in the Annals of Oncology today by Rare Cancers Europe (RCE) calls for new methodologies to be applied to clinical studies in rare cancers. RCE - a multi-stakeholder initiative representing patient associations, medical societies and industry - is calling both the community of researchers and European authorities to address...

2014-09-30 08:30:56

Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept. 30, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy....

2014-09-29 12:30:45

BOGOTA, Colombia, Sept. 29, 2014 /PRNewswire/ -- Cancer Treatment Institute of Colombia has announced a promising new drug treatment: a carefully formulated, first-of-its-kind combination of salinomycin and 3-bromopyruvate (3-BrPA) that has already proven successful at treating multiple types of cancer. The team of medical researchers behind this novel treatment are optimistic that it could significantly improve outcomes for many patients who have exhausted current therapeutic...

Study Finds Many Patients Excluded From Clinical Trials Due To Prior Cancer
2014-09-29 03:46:37

UT Southwestern Medical Center Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50 lung cancer clinical trials examined, more than 80 percent excluded patients with prior cancer from participating, according to the study published in the Journal of the National Cancer Institute. The exclusion criterion was even applied in more than...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related